40 results about "Reducing anxiety" patented technology

A method for improving the bioavailability of a bioactive substance includes subjecting the bioactive substance to laser radiation. The laser radiation modifies the bioactive substance to thereby modify reactions relating thereto in the body. The method enables reductions in inflammation associated with autoimmune diseases, modification of reaction by-products in the body, increased homogenization and flattening of molecular shape and improved methylation. The improved methylation can be utilized to reduce homocysteine blood levels, and to reduce anxiety, depression, paranoia, hostility, somatization (perception of bodily distress) and obsessive-compulsive symptoms. Enhanced nitric oxide generation from modified L-arginine can be used to reduce systolic and diastolic blood pressure, lower total and LDL cholesterol levels, and improve the ratio of total to HDL cholesterol. Increased depth of penetration of sparse constructive nodes of laser radiation may increase the range of photodynamic therapy applications and a wide range of in vitro and in vivo modifications of molecular shape and activity. Laser acoustic resonance can be utilized to increase the homogeneity of crystals, or favor the generation of novel or preferred crystalline forms.

Provided is a composition and method for modulating serotonergic receptor expression, reducing anxiety-like behavior and stress-induced inflammatory response in a pediatric subject, the method including administering to the pediatric subject a nutritional composition including lactoferrin from a non-human source and a prebiotic composition including polydextrose and / or galactooligosaccharides. Further provided is a method for reducing constipation in a pediatric subject by providing a nutritional composition including lactoferrin from a non-human source and a prebiotic composition including polydextrose and / or galactooligosaccharides.

A method for improving the bioavailability of a bioactive substance includes subjecting the bioactive substance to laser radiation. The laser radiation modifies the bioactive substance to thereby modify reactions relating thereto in the body. The method enables reductions in inflammation associated with autoimmune diseases, modification of reaction by-products in the body, increased homogenization and flattening of molecular shape and improved methylation. The improved methylation can be utilized to reduce homocysteine blood levels, and to reduce anxiety, depression, paranoia, hostility, somatization (perception of bodily distress) and obsessive-compulsive symptoms. Enhanced nitric oxide generation from modified L-arginine can be used to reduce systolic and diastolic blood pressure, lower total and LDL cholesterol levels, and improve the ratio of total to HDL cholesterol. Increased depth of penetration of sparse constructive nodes of laser radiation may increase the range of photodynamic therapy applications and a wide range of in vitro and in vivo modifications of molecular shape and activity. Laser acoustic resonance can be utilized to increase the homogeneity of crystals, or favor the generation of novel or preferred crystalline forms.

The present invention is directed to the production of PKC isozyme epsi (PKCepsi)-deficient cells and non-human animals. The present invention is further directed to the identification of PKCepsi as a target for drugs that reduce anxiety. According to the present invention, PKCepsi-inhibiting compounds act in synergy with drugs acting at the GABAA receptor. The present invention is also directed to the use of modulators of PKCepsi to modulate alcohol consumption, self-administration of other drugs of abuse, and the effects of alcohol consumption as well as the use of inhibitors of PKCepsi, either alone or in conjunction with allosteric agonists of GABAA receptors, to treat conditions, such as addiction, withdrawal syndrome, skeletal muscle spasms, convulsive seizures, and epilepsy, that are amenable to treatment by allosteric agonists of GABAA receptors. Additional aspects of the present invention are diagnostic methods for identifying individuals at risk for becoming alcoholics or abusers of other drugs and kits for performing such diagnostic methods. The present invention relates to: cells and non-human animals deficient for the PKC isozyme epsi (PKCepsi); the use of PKCepsi as a target for drugs; the use of inhibitors of PKCepsi in methods of reducing anxiety and treating conditions associated with insufficient activity of the GABAA receptor; the use of modulators of PKCepsi in methods of modulating alcohol consumption, modulating self-administration of other drugs of abuse, and altering the effects of alcohol; pharmaceutical compositions comprising inhibitors of PKCepsi and allosteric agonists of GABAA receptors; and the identification of individuals with enhanced susceptibility to alcoholism or other forms of addiction.

Disclosed are methods comprising: receiving data representing the physical location, movement, social environment, emotional state and nutritional behavior; comparing this data and nutritional behaviors throughout the day to goals for achieving a balance of macronutrients (food groups) and micronutrients, represented by a Nutrition Score; determining the positive and negative impact of physical and social environment on nutritional behaviors and emotional state; targeting messages, cues, tips and coping tactics based on acquired parameters to help change the individuals response to the environment and other factors, improve mood, reduce anxiety and improve nutritional behavior; and allowing for real-time connectivity to a support system. Also disclosed are methods where the acquired parameters are transmitted to health care professionals, such as dietitians, therapists, physicians, health coaches, through real-time connectivity to acquired parameters, health professionals can more effectively coordinate and target care.

The present invention is designed to prevent or reduce anxiety in child or adolescent patients undergoing dental or medical procedures through a design to conceal or hide elements of a traditional syringe. The use of an opaque sleeve or exterior surface shaped in a manner other than a tube is used to conceal the interior of the syringe barrel, mask the plunger, and partially obstruct the view of the cannula assembly.

Provided is a composition and method for modulating serotonergic receptor expression, reducing anxiety-like behavior and stress-induced inflammatory response in a pediatric subject, the method including administering to the pediatric subject a nutritional composition including lactoferrin from a non-human source and a prebiotic composition including polydextrose and / or galactooligosaccharides. Further provided is a method for reducing constipation in a pediatric subject by providing a nutritional composition including lactoferrin from a non-human source and a prebiotic composition including polydextrose and / or galactooligosaccharides.

Methods, systems and devices for reducing anxiety, including increasing relaxation and / or calm. In some variations these methods may include reducing anxiety, increase relaxation and / or calm by non-invasive temperature regulation of the frontal cortex prior to and / or during sleep. The subject may have an anxiety disorder, or may not have a diagnosed anxiety disorder.

A garment to reduce an animal's anxiety, fearfulness, overexcitement, or a combination thereof. The garment may include a central portion, flaps extending from opposite sides of the central portion, and, in some cases, a cinching member that extends from a central area of the central portion. The flaps may be fastened together around the chest and stomach of the animal, and the cinching member may be fastened to the central portion or one or more flaps to tighten the garment further, applying pressure to reduce anxiety, fearfulness, or over-excitement. Straps may be provided to secure the garment to the animal's neck. One material that may be used in making the garment is a fabric made of 55% cotton, 35% polyester, and 10% spandex. The animal may generally be any animal with four legs, for example, a dog or cat, or two arms and two legs, for example, a monkey.

A system for reducing anxiety in an individual is provided. The system is capable of applying deep pressure to activate a Vegetative Skin Reflex. The system includes a wearable device constructed for covering at least a portion of a body of the individual. The wearable device includes individually expandable units for applying pressure to a specific body region of the individual when expanded and an expandable support unit for expanding and countering the pressure applied to the specific body region by each individual expandable pressure unit.

The present invention relates to a drug suitability assessment method for the prevention or treatment of anxiety disorders using the cholinergic type II theta rhythm, and, more specifically, to a method for detecting individuals suffering from anxiety disorders induced by an abnormality occurring in the cholinergic system using the type II theta rhythm profile which is based on findings that the cholinergic type II theta rhythm is lower in an animal anxiety model than in normal subjects and that cholinergic drug treatment induces the cholinergic type II theta rhythm to return to normal and reduces anxiety and thereby making it possible to determine if a subject can be appropriately administered with a cholinergic drug and to monitor progress after cholinergic drug treatment.

The invention relates to a method and a system for reducing anxiety of patients before and during e.g. MR scanning examinations. The method is based on displaying images on walls (106,107) of the scanner room (100) so that when the patient enters the scanner room, then an image is displayed on a wall visible to the patient, e.g. a wall adjacent to the entry door (103). When the patient is laying on the table (102) of the scanner (101) the projection of images is switched to another wall by reflecting the projected images using e.g. a mirror which is moved into the light rays emitted by an image projector.

Provided is a human RE2-L protein, as well as the encoding nucleic acid, methods for screening for agents capable of modulating RE2-L related activity and treating RE2-L-mediated conditions. Further provided are animal models useful for screening agents capable of ameliorating or reducing anxiety related disorders and obsessive-compulsive disorders.

Methods of treating anxiety disorders or reducing anxiety-related behaviors. The methods include administering a therapeutically effective amount of ketone supplementation, such as butanediol, ketone esters (e.g., 1,3-butanediol-acetoacetate diester) and / or ketone salts (e.g., beta-hydroxybutyrate-mineral salt), chronically, sub-chronically, or acutely, with or without admixture with a medium chain triglyceride or in combination. It was determined herein that ketone supplementation reduced anxiety in rats on elevated plus maze as measured by less entries to closed arms, more time spent in open arms, more distance travelled in open arms, and delayed latency to entrance to closed arms, when compared to control. Along with reducing anxiety-related behavior, the chronic, sub-chronic, and acute ketone supplements also caused significant elevation of blood βHB levels and changed blood glucose levels.

Compositions are described comprising at least partially defatted meal from a plant source containing protein-bound tryptophan, preferably squash seeds, and, optionally, a carbohydrate source provided in an amount capable of facilitating transport of in vivo generated tryptophan across the blood brain barrier. Also described are dietary supplements, foods and beverages comprising the composition of the invention to reduce anxiety.

Described are reminiscence therapy and media sharing platform, methods, and systems for a patient user which provide an immediate and First Mobile Application positive impact on emotional functioning inpatients with dementia, major neurocognitive disorders, social isolation, traumatic brain injury (TBI), and psychiatric conditions such as posttraumatic stress disorder, by reducing anxiety, depression, and overall emotional distress.

The present invention provides compositions and uses thereof for reducing anxiety and / or impulsivity, including, for example, suicidality, in a subject undergoing treatment with a serotonin reuptake inhibitor (SRI) comprising administering to the subject an effective amount of a SRI and an effective amount of a 5-HT1A receptor partial agonist / antagonist. In addition, the present invention provides dosing regimens for various SSRIs which can also reduce anxiety and / or impulsivity, including, for example, suicidality in a subject undergoing treatment with an SSRI. Kits including daily dosing regimens of various SSRIs are also provided.

The invention provides a medicament for treating irritable bowel syndrome with spleen-stomach damp-heat syndrome, comprising medicinal materials: Radix Scutellariae, Rhizoma Coptidis, Herba Portulacae, Radix Sophorae Flavescentis, Radix Pulsatillae, Rhizoma Atractylodis, Semen Coicis, Poria, Radix Puerariae, Radix Curcumae, Fructus Aurantii, Rhizoma Cyperi, Pericarpium Citri Reticulatae, Pericarpium Citri Reticulatae, Cortex Magnoliae Officinalis, Radix Notoginseng, Radix Paeoniae Alba, Radix Paeoniae Rubra, Fructus Crataegi, Herba Lophatheri, Rhizoma Acori Tatarinowii and Radix Glycyrrhizae Preparata. The medicament is effective in clearing heat and eliminating damp, relieving spasm and pain and cooling blood and removing stasis through formulation compatibility with respect to traditional Chinese medicine differentiation of the irritable bowel syndrome with spleen-stomach damp-heat syndrome in connection with clinical manifestation of a patient. The medicament is well functional in treating a patient with the irritable bowel syndrome with spleen-stomach damp-heat syndrome in terms of clinical symptoms and living quality; can reduce recurrence of this disease, thus reducing anxiety and depression.

The present invention is directed to the production of PKC isozyme epsilon (PKCepsilon)-deficient cells and non-human animals. The present invention is further directed to the identification of PKCepsilon as a target for drugs that reduce anxiety. According to the present invention, PKCepsilon-inhibiting compounds act in synergy with drugs acting at the GABAA receptor. The present invention is also directed to the use of modulators of PKCepsilon to modulate alcohol consumption, self-administration of other drugs of abuse, and the effects of alcohol consumption as well as the use of inhibitors of PKCepsilon, either alone or in conjunction with allosteric agonists of GABAA receptors, to treat conditions, such as addiction, withdrawal syndrome, skeletal muscle spasms, convulsive seizures, and epilepsy, that are amenable to treatment by allosteric agonists of GABAA receptors. Additional aspects of the present invention are diagnostic methods for identifying individuals at risk for becoming alcoholics or abusers of other drugs and kits for performing such diagnostic methods. The present invention relates to: cells and non-human animals deficient for the PKC isozyme epsilon (PKCepsilon); the use of PKCepsilon as a target for drugs; the use of inhibitors of PKCepsilon in methods of reducing anxiety and treating conditions associated with insufficient activity of the GABAA receptor; the use of modulators of PKCepsilon in methods of modulating alcohol consumption, modulating self-administration of other drugs of abuse, and altering the effects of alcohol; pharmaceutical compositions comprising inhibitors of PKCepsilon and allosteric agonists of GABAA receptors; and the identification of individuals with enhanced susceptibility to alcoholism or other forms of addiction.

The present invention discloses a traditional Chinese medicine composition for treatment of insomnia due to coronavirus pneumonia. A basic prescription of the traditional Chinese medicines is composedof the following traditional Chinese medicine raw materials in parts by weight: 10-25 parts of angelica sinensis, 8-25 parts of raw white peony root, 3-18 parts of radix bupleuri, 8-20 parts of poriacum ligno hospite, 6-18 parts of fried bighead atractylodes rhizome, 5-15 parts of fried radix stemonae, 20-40 parts of cortex albiziae, 6-15 parts of rhizoma chuanxiong, 8-20 parts of spina date seeds, 6-18 parts of rhizoma anemarrhenae and 3-9 parts of honey-fried licorice root. The traditional Chinese medicine composition is concise and appropriate in compatibility, and efficacy is verified byclinical application. The traditional Chinese medicine composition can effectively alleviate symptoms of the insomnia of COVID-19, reduce anxiety of patients to a certain extent, improve quality of sleep of the patients and alleviate traumatic response complex symptoms of chest tightness, palpitation, fatigue, palpitations, etc. of COVID-19 patients after new coronary pneumonia.

The invention discloses bifidobacterium lactis Probio-M8 capable of relieving and treating coronary heart disease and application of the bifidobacterium lactis Probio-M8. Clinical population tests indicate that the bifidobacterium lactis Probio-M8 is good in safety, and can reduce anxiety and depressive emotions of patients with coronary heart disease, relieve angina pectoris symptoms of the patients and reduce the content of low-density lipoprotein cholesterol in blood. The bifidobacterium lactis Probio-M8 has obvious effects of relieving and treating the coronary heart disease and anxiety and reducing cholesterol level, and has a huge application prospect in preparation of products and functional products for relieving and treating the coronary heart disease.

A computer system for reorienting, reducing anxiety, and / or reducing delirium risk of a patient in a hospital is provided. The computer has a central processing unit (CPU) for executing machine instructions for a passive and active module and a memory for storing the machine instructions. The machine instructions implement functions when executed by the CPU. Patient-specific content is inputted into the CPU. The system then communicates the patient-specific content from the CPU to the patient by displaying and looping the patient-specific content such that any point of the loop of the patient-specific content helps reorient and reduce anxiety and delirium risk.

The present invention provides methods, compositions, and kits for treating anxiety -related disorders, including OCD and SAD, and for reducing anxiety, obsessive behavior, or compulsive behavior in subjects in need thereof.

The invention belongs to the technical field of functional ointments, and provides an external nasal ointment with the effects of promoting weight loss and smoking cessation. The external nasal ointment comprises the following raw materials in percentage by mass: 10-50% of kokum butter, 0.5-50% of olive oil, 0-50% of sesame oil, 0.5-50% of rosa canina fruit oil, 0.1-5% of peppermint oil, 0.1-5% ofblack pepper essential oil, 0.5-50% of candelilla wax, and 1-5% of grapefruit essential oil. The product disclosed by the invention is a light yellow paste, and achieves the effects of inhibiting thecraving for food, increasing the effect of exercising the body, and relieving the anxiety caused by smoking cessation through improving the psychological and physical feelings (including relieving rhinitis, reducing anxiety, relieving tension, reducing depression, relieving body soreness, improving digestion, promoting sleep and relieving insomnia) of the human body, and finally purposes of weight loss and smoking cessation are achieved.

A compound including a prodrug having a psychoactive base substance attached to an amino acid. A method of treating an individual, especially in substance-assisted psychotherapy, by administering proMDMA or a proMDMA-like compound to the individual, metabolizing the prodrug, and releasing the MDMA or MDMA-like substance in the individual. A method of reducing anxiety while administering MDMA, by providing a slow release of MDMA or an MDMA-like substance and thereby reducing anxiety in the individual at the onset of administration. A method of personalized medicine, by evaluating an individual and determining if there are characteristics of the individual present that would not be suitable for MDMA treatment and administering proMDMA or a proMDMA-like substance to the individual. A method of reducing abuse of MDMA, by administering proMDMA or a proMDMA-like substance, and providing a delayed and attenuated effect of MDMA or a MDMA-like substance, thereby reducing abuse.

Methods of treating anxiety disorders or reducing anxiety-related behaviors. The methods include administering a therapeutically effective amount of ketone supplementation, such as butanediol, ketone esters (e.g., 1,3-butanediol-acetoacetate diester) and / or ketone salts (e.g., beta-hydroxybutyrate-mineral salt), chronically, sub-chronically, or acutely, with or without admixture with a medium chain triglyceride or in combination. It was determined herein that ketone supplementation reduced anxiety in rats on elevated plus maze as measured by less entries to closed arms, more time spent in open arms, more distance travelled in open arms, and delayed latency to entrance to closed arms, when compared to control. Along with reducing anxiety-related behavior, the chronic, sub-chronic, and acute ketone supplements also caused significant elevation of blood βHB levels and changed blood glucose levels.

A supplement that produces an increased feeling of alertness and reduces anxiety, or produce a feeling of calmness is described. In an exemplary embodiment, the supplement is all natural, and contains no or essentially no synthesized chemical. The supplement or the therapeutic ingredients, such as the ingredients within a capsule, may only contain plant matter. The plant matter may include plant roots and leaves, for example. The supplement and more specifically the active ingredient of the supplement may include, piper methysticum (kava kava root), brahmi (bacopa), ashwagandha (winter cherry). These three ingredients may be the primary active or therapeutic ingredients and may be provided in an effective amount to produce a feeling of alert calmness.